Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Amyloidosis: disease caused by amyloid
3. Amyloidosis facts: morbidity and mortality
4. Medicine demands precision
5. What is, and what is not amyloidosis?
6. Amyloidosis characteristics
7. Other diseases in which amyloid occurs
8. Protein misfolding but not amyloid or amyloidosis
9. Amyloid deposits
10. The nature of amyloid deposits
11. Electron micrograph of spleen amyloid
12. Congo red staining of amyloid
13. Amyloid fibrils and cross-beta structure
14. Model of amyloid fibril structure
15. Components of amolyid deposites
16. Clinical amyloidosis: preface
17. Clinical amyloidosis: overview
18. Acquired systemic amyloidosis
19. Hereditary systemic amyloidosis
20. Acquired local amyloidosis
21. Hereditary local amyloidosis
22. Acquired local amyloid deposits
23. Hereditary local amyloid deposits
24. Amyloid fibrillogenesis: preface
25. Amyloid fibrillogenesis in-vivo
26. Amyloid fibrillogenesis in-vitro
27. Amyloid fibrillogenesis
28. Lysozyme amyloid fibrillogenesis
29. Amyloidosis: unanswered questions
30. Tissue damage by amyloid (1)
31. Tissue damage by amyloid (2)
32. Tissue damage by amyloid (3)
33. In-vivo vs. in-vitro cell culture conditions
34. Direct physical damage by amyloid deposits
35. Organ transplantation in apoAI amyloidosis
36. Cardiac amyloidosis (1)
37. Cross-section of amiloidogenic heart
38. Systemic apoAI amyloidosis: SAP scintigraphy
39. Systemic apoAI amyloidosis: splenectomy
40. Extra-dural AL amyloidoma
41. Localised ocular AL amyloidosis
42. Diversity of AL amyloidosis
43. Hereditary transthyretin amyloidosis
44. Pathogenicity of misfolded proteins
45. Cautionary tales
46. Imaging amyloid in vivo
47. Diagnosis of amyloidosis
48. Serum amyloid P component (SAP)
49. SAP and CRP have lectin fold
50. Appearance of SAP in EM
51. 3D structure of SAP: face view
52. 3D structure of SAP: side view
53. SAP-MObDG binding
54. Lectin fold proteins
55. SAP and amyloid deposits
56. SAP: diagnosis and quantification of amyloid
57. UK NHS national amyloidosis center
58. SAP scintigraphy for amyloidosis
59. Explosive late onset evolution of AA amyloidosis
60. Diversity of AL amyloidosis (1)
61. Diversity of AL amyloidosis (2)
62. Diversity of AL amyloidosis (3)
63. Treatment of amyloidosis
64. Treatment of systemic amyloidosis (1)
65. Treatment of systemic amyloidosis (2)
66. Regression of AA amyloidosis
67. SAA and outcome in AA amyloidosis
68. Regression of AL amyloid
69. Treatment of AL amyloidosis
70. Serum free light chain assay
71. Serum free light chains in AL amyloidosis
72. Survival after chemotherapy in AL amyloidosis
73. DNA screening for hereditary amyloidosis
74. Fibrinogen A alpha-chain amyloidosis
75. Treatment of fibrinogen amyloidosis
76. New treatments for amyloidosis?
77. SAP and amyloidogenesis
78. Inhibitors of SAP binding
79. SAP scintigraphy before and after CPHPC infusion
80. Targeted depletion of plasma SAP by CPHPC
81. The SAP-CPHPC complex
82. Clinical studies of CPHPC in systemic amyloidosis
83. Conclusions

Topics Covered

• What is, and what is not amyloidosis
• Amyloid deposits
• Clinical amyloidosis
• Amyloid fibrillogenesis
• Tissue damage by amyloid
• Imaging amyloid in vivo
• Treatment of amyloidosis

Links

Series:

• Protein Folding, Aggregation and Design

Categories:

• Biochemistry
• Clinical Practice

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on April 17, 2016

Financial Disclosures

• Prof. Mark Pepys has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.